Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD Makes New Investment in Teva Pharmaceutical Industries Ltd. $TEVA

Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD bought a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 997,617 shares of the company’s stock, valued at approximately $33,799,000. Teva Pharmaceutical Industries comprises 4.2% of Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD’s investment portfolio, making the stock its 4th biggest position.

Several other institutional investors also recently bought and sold shares of TEVA. IFP Advisors Inc increased its holdings in shares of Teva Pharmaceutical Industries by 1.1% during the 2nd quarter. IFP Advisors Inc now owns 143,876 shares of the company’s stock valued at $4,875,000 after purchasing an additional 1,532 shares in the last quarter. Waverly Advisors LLC lifted its stake in shares of Teva Pharmaceutical Industries by 7.7% in the 2nd quarter. Waverly Advisors LLC now owns 12,814 shares of the company’s stock valued at $434,000 after purchasing an additional 918 shares during the period. Nykredit A S purchased a new stake in Teva Pharmaceutical Industries during the second quarter worth $11,526,000. California State Teachers Retirement System grew its position in Teva Pharmaceutical Industries by 3,376.3% during the second quarter. California State Teachers Retirement System now owns 43,270,486 shares of the company’s stock valued at $1,466,004,000 after buying an additional 42,025,742 shares during the period. Finally, HB Wealth Management LLC acquired a new stake in Teva Pharmaceutical Industries during the second quarter valued at $295,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Eliyahu Kalif sold 106,563 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $34.10, for a total value of $3,633,798.30. Following the sale, the executive vice president owned 65,621 shares of the company’s stock, valued at $2,237,676.10. The trade was a 61.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 1.2%

TEVA opened at $36.81 on Wednesday. The company has a debt-to-equity ratio of 1.56, a current ratio of 0.88 and a quick ratio of 0.67. The company’s 50 day simple moving average is $34.76 and its two-hundred day simple moving average is $33.31. The firm has a market capitalization of $42.89 billion, a price-to-earnings ratio of 61.35, a price-to-earnings-growth ratio of 4.53 and a beta of 0.87. Teva Pharmaceutical Industries Ltd. has a 1-year low of $18.21 and a 1-year high of $38.37.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. The company had revenue of $4.14 billion for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. Analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.94 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on TEVA. UBS Group upped their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a research report on Friday, September 4th. Weiss Ratings upgraded Teva Pharmaceutical Industries from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, August 21st. Piper Sandler lifted their price target on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a research note on Tuesday, July 28th. Barclays upped their price target on Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Finally, Wall Street Zen downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.89.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.